Ovarian Cancer Stage IV
27
8
8
10
Key Insights
Highlights
Success Rate
83% trial completion
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 52/100
7.4%
2 terminated out of 27 trials
83.3%
-3.2% vs benchmark
11%
3 trials in Phase 3/4
30%
3 of 10 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 10 completed trials
Clinical Trials (27)
Study of Acute Normovolemic Hemodilution (ANH) in People With Ovarian Cancer Who Are Having Cytoreductive Surgery
Prehabilitation in Gynaecological Cancer Patients
Phenotypic Characterization Tumor-infiltrating Lymphocytes at Diagnosis and After Chemotherapy in Ovarian Cancer
A Combination Therapy Strategy to Prevent Anti-PD-1 Therapy Resistance in Metastatic Ovarian Cancer Patients
Tart Cherry Juice as a Dietary Supplement for the Prevention of Paclitaxel-Induced Neuropathy
Exercise as a Preventive Agent to Combat Immobility in Patients With Ovarian or Endometrial Cancers Receiving Chemotherapy
Retarded Surgery Following Neoadjuvant Chemotherapy in Advanced Ovarian Cancer
Predicting Outcome of Cytoreduction in Advanced Ovarian Cancer
PEMBRO With Chemo in Neo Adj Treatment of Ovarian Cancer .
Sequential CD146 and GPC3 CAR-T Cell Therapy in Advanced Ovarian Cancer
Microdevice In Ovarian, Fallopian Tube, And Peritoneal Cancer
NEoadjuvant Olaparib Combination OvArian Cancer Targeted Study
Neo-adjuvant Pembrolizumab in Primary Stage IV Ovarian Cancer
Tumor Microenvironment in Ovarian Cancer
PIPAC Nab-pac for Stomach, Pancreas, Breast and Ovarian Cancer
Oregovomab in Combination With Bevacizumab Plus Chemo in BRCA Wild Type Platinum Sensitive Recurrent Ovarian Cancer
Dynamic Monitoring of ctDNA Predicts Recurrence of Advanced Ovarian Cancer After Primary Treatments
Self-Advocacy Serious Game in Advanced Cancer
Survival Impact of Internal Mammary or Supraclavicular Lymphadenectomy
Impact of Gated PET/CT in the Diagnosis of Advanced Ovarian Cancer